Actively Recruiting
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2024-06-28
3600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the effects of combining radiotherapy with molecular agents, such as immunotherapy and signaling pathway modulators, in cancer patients. This research focuses especially on patients with metastatic disease who often receive both treatments. The goal is to better understand the side effects that may occur when these two treatment types are given together compared to when they are given alone. The study collects data from patients receiving radiotherapy alongside molecular therapies for cancer treatment. Radiotherapy may be delivered using 3D conventional, IMRT, or SBRT techniques. Patients' diagnoses, treatment doses, types of targeted therapies, and side effects are recorded. This registry aims to identify whether more severe side effects (grade 3 or above) occur with combined treatments than what is known from existing literature. Participants will provide information about their side effects and quality of life. Physicians will also contribute clinical data including diagnosis and treatment details. The primary outcome measured is the number of participants experiencing severe side effects within one year. This observational registry began in 2019 and will continue collecting data until at least September 2025.
CONDITIONS
Brief Title
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Consent to be part of the AtTRIBut registry
- Prior histological diagnosis of primary cancer
- If metastatic, radiological or pathological evidence of metastasis
- Age over 18 years
- Receiving a molecular therapy
- Indicated to receive radiotherapy
- Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques
You will not qualify if you...
- Refusal or inability to receive radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 year
Participants receiving radiotherapy and molecular agents are observed to collect information on side effects, treatment doses, and quality of life.
Visits as needed to report side effects and quality of life
Trial Site Locations
Total: 1 location
1
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada, H2X 0A9
Actively Recruiting
Research Team
M
Mom Phat, RN
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here